Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
OncoTargets and Therapy. 2016;Volume 9:4181-4186 
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
The Lancet Oncology. 2012;13(1):e23-e31
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Signal Transduction and Targeted Therapy. 2019;4(1):
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Cancer Research and Treatment. 2019;51(2):623-631
EFFECTIVENESS OF TREATMENTS IN ADVANCED NON-SMALL CELL LUNG CANCER WITH EXON 20 INSERTION EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
Respirology. 2018;23:168-168
Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer
Scientific Reports. 2016;6(1):
Pre-clinical Modeling of Osimertinib for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Journal of Thoracic Oncology. 2019;
Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
British Journal of Cancer. 2007;96(2):399-399
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
Clinical Lung Cancer. 2017;18(3):324-332.e1
Clinical and surgical implications of EGFR mutations in non-small cell
lung cancer
Annals of Global Health. 2016;82(3):472